PHILADELPHIA (August 23, 2019) — Evelyn González and Shannon Lynch, MPH, PhD, have received a two-year grant for $125,000 from The Pennsylvania Department of Human Services to provide liver cancer and hepatitis education to at-risk communities in the Philadelphia area. Up to 70 percent of liver cancer cases are caused by modifiable factors, including drug or alcohol use, obesity, diabetes, and infection with hepatitis B or C.

PHILADELPHIA (August 20, 2019) – The immunostimulatory monoclonal antibody elotuzumab, given in combination with lenalidomide and dexamethasone, is approved for the treatment of patients with relapsed or refractory multiple myeloma. The drug binds signaling lymphocytic activation molecule family member 7 (SLAMF7), a protein that is highly expressed on the surface of myeloma cells.

PHILADELPHIA (August 16, 2019) – Recently, Fox Chase Cancer Center researchers found a potential way to sensitize a new subset of patients with high-grade serous ovarian carcinoma to PARP inhibitors, a promising drug used in some cases of this disease. Disruption of HSP90 function can lead to death of ovarian cancer cell lines without known defects in DNA repair mechanisms, such as BRCA1/2 mutations, when used in combination with a PARP inhibitor.